ENBI.CN

Entheon Biomedical Corp.

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

Expanding brand awareness and access to HaluGen's Psychedelics Genetic Test KitVancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge b... Read More...

Eric Sprott Announces Holdings in Entheon Biomedical Corp., (Formerly, MPV Exploration Inc.)

Toronto, Ontario--(Newsfile Corp. - December 3, 2021) - Eric Sprott announces that, today, 600,000 common share purchase warrants (Warrants) of Entheon Biomedical Corp., (held by 2176423 Ontario Ltd., a corporation he beneficially owns) expired unexercised representing a decrease in holdings of approximately 4.2% of the outstanding common... Read More...

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

To drive brand awareness of, and access to, HaluGen's Psychedelics Genetic Test KitVancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon"), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement w... Read More...

Silo Wellness and Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Announces Psychedelics Genetic Test Kit Partnership

TORONTO, June 17, 2021 -- Silo Wellness Inc. (β€œSilo Wellness” or β€œthe Company”) (CSE: SILO) (FRA: 3K70) (OTC: SILFF), a functional and psilocybin mushroom company offering psychedelic wellness retreats, and Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon"), a biotechnology company focused on developing psychedeli... Read More...

KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021

Featuring presentations by eminent psychedelics companies and industry leaders including keynote speakers, Rick Doblin, MAPS and Amy Emerson, MAPS Public Benefit CorporationNEW YORK, Jan. 11, 2021 -- KCSA Strategic Communications, an integrated strategic communications firm specializing in public relations, investor relations and social m... Read More...

Entheon Biomedical Closes Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 25, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it has closed a non-brokered private placement financing for total gross proceeds of CAD $3,174,374.25 (the "Placement"). The majority of the Placement was subscribed for by strat... Read More...

Entheon Biomedical Announces Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2020) - Β Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it is proceeding with a fully allocated, non-brokered private placement financing of 4,266,997 Units (the "Units") at a price of CDN$0.75 per Unit for gross proceeds of CDN$3,200... Read More...

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Psygen Labs Inc. ("Psygen"). ... Read More...

Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. ("Wonder Scientific").Wonder Scientific's team ... Read More...